BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 5,771 Shares

by · The Cerbat Gem

BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) insider Sarah Aebersold sold 5,771 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total transaction of $130,770.86. Following the completion of the sale, the insider now directly owns 80,094 shares of the company’s stock, valued at approximately $1,814,930.04. This trade represents a 6.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Sarah Aebersold also recently made the following trade(s):

  • On Monday, March 17th, Sarah Aebersold sold 2,695 shares of BioLife Solutions stock. The stock was sold at an average price of $25.44, for a total transaction of $68,560.80.
  • On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The stock was sold at an average price of $24.96, for a total value of $140,574.72.
  • On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total value of $27,275.00.
  • On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $6,484.80.

BioLife Solutions Stock Performance

NASDAQ:BLFS traded down $1.34 during mid-day trading on Thursday, hitting $22.44. 591,144 shares of the company’s stock traded hands, compared to its average volume of 358,590. The firm has a 50 day moving average of $26.11 and a two-hundred day moving average of $25.54. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -21.17 and a beta of 2.04. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55.

BioLife Solutions (NASDAQ:BLFS – Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The firm had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. During the same quarter in the previous year, the company earned ($0.21) earnings per share. On average, equities analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BLFS has been the subject of a number of research analyst reports. KeyCorp increased their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. HC Wainwright increased their target price on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Northland Securities upped their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. StockNews.com downgraded shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Monday. Finally, Benchmark reiterated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

Read Our Latest Stock Analysis on BioLife Solutions

Institutional Investors Weigh In On BioLife Solutions

A number of hedge funds have recently added to or reduced their stakes in the stock. D.A. Davidson & CO. grew its position in shares of BioLife Solutions by 1.3% during the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock worth $1,069,000 after buying an additional 519 shares during the period. Stifel Financial Corp raised its position in shares of BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares during the period. 1620 Investment Advisors Inc. boosted its holdings in shares of BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after buying an additional 675 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of BioLife Solutions by 27.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock valued at $117,000 after purchasing an additional 950 shares during the period. Finally, Steward Partners Investment Advisory LLC acquired a new position in BioLife Solutions during the 4th quarter worth approximately $26,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

(Get Free Report)

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Featured Stories